ACADIA Pharmaceuticals Announces Appointment of Roger G. Mills, M.D., as Executive Vice President, Development
SAN DIEGO, June 5 /PRNewswire-FirstCall/ — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointment of Roger G. Mills, M.D., as Executive Vice President, Development, effective June 30, 2006. Dr. Mills will be responsible for leading ACADIA’s global drug development activities and will report to Uli Hacksell, Ph.D., Chief Executive Officer.
“Roger Mills is an exceptionally skilled and experienced drug development executive and we are delighted to add a leader of his stature to our team,” said Dr. Hacksell. “Roger has a proven track record of leading successful drug development efforts in multiple therapeutic areas, most recently exemplified by his key roles in the development of Sutent(R) while at Pfizer and Tamiflu(R) during his tenure at Gilead. His extensive experience will be a major asset to ACADIA as we continue to advance our four proprietary Phase II-stage clinical programs.”
Dr. Mills brings to ACADIA more than 18 years of experience in the pharmaceutical industry. Most recently, he held the position of Vice President, Development Pfizer Global R&D for a five-year period. In this capacity, he was responsible for the management and direction of drug development activities at the Pfizer site in La Jolla, California, and played a key role in the development of Sutent, a new multikinase inhibitor for patients with advanced renal cell carcinoma and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Mills held senior clinical management positions at Gilead, where he served as project leader in the development of Tamiflu, a leading treatment for influenza, and at Abbott Laboratories, where he played an important role in the development of antiviral drugs. Earlier in his career, he held several senior positions at the Wellcome Foundation, including Scientific Advisor for Group Marketing and Therapeutic Area Head, Cardiovascular. Dr. Mills received his medical degree at the Charing Cross Hospital Medical School in London and his specialized medical training at the Royal College of General Practitioners in London.
“I am delighted to join ACADIA, which has successfully generated a promising clinical pipeline and is at a particularly exciting stage of development,” said Dr. Mills. “ACADIA has the rare combination of a strong management team coupled with a deep and rapidly maturing clinical pipeline that may provide innovative approaches to the treatment of major unmet medical needs.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five Phase II-stage clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson’s disease, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA’s product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA’s corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the advancements, benefits, and potential of ACADIA’s programs and drug candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, and litigation. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2005 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer